ARMP ▲ +19.8% - Armata Pharmaceuticals, Inc. $ARMP ARMP ARMP ARMP - Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development Armata Pharmaceuticals shares rose 19.8% after the company announced it received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support Phase 3 development of its AP-SA02 therapeutic candidate. Non-dilutive funding does not require shareholders to issue new equity, making it an accretive form of capital that can extend the company's cash runway and reduce the need for dilutive financing. 23-SEP-2026 07:00 AM ET